JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prevalence and Clinical Outcomes of Human Epidermal Growth Factor Receptor 2 Expression in Patients With Advanced Urothelial Carcinoma

  • 0Oncology Center, Hospital Medica Sur, Mexico City, Mexico.
World Journal of Oncology +

|

January 24, 2025

|

January 24, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Human epidermal growth factor receptor 2 (HER2) expression is common in urothelial carcinoma and linked to poorer outcomes. HER2-positive tumors indicate a worse prognosis, highlighting potential for targeted therapies.

Area Of Science

  • Oncology
  • Molecular Pathology
  • Urologic Oncology

Background

  • Urothelial carcinoma has a poor prognosis and limited treatment options.
  • The role of human epidermal growth factor receptor 2 (HER2) in urothelial carcinoma is not well-defined, with conflicting prior research.
  • Targeted therapies for urothelial carcinoma necessitate a clearer understanding of prognostic and predictive biomarkers.

Purpose Of The Study

  • To investigate the prevalence and prognostic significance of HER2 expression in urothelial carcinoma.
  • To evaluate the association between HER2 status and clinicopathological features and survival outcomes.
  • To explore the potential of HER2 as a therapeutic target in urothelial carcinoma.

Main Methods

  • Retrospective analysis of advanced urothelial carcinoma cases (2017-2022).
  • Prospective determination of HER2 status using immunohistochemistry (Leica CB11 antibody).
  • Collection and analysis of patient data, tumor characteristics, and survival outcomes.

Main Results

  • HER2 expression (≥1+) was found in 54.4% of analyzed urothelial carcinoma samples.
  • HER2-positive (3+ IHC) tumors were associated with higher histological grade (grade 3).
  • Patients with HER2-positive tumors showed significantly shorter overall survival (13.0 months) compared to HER2-negative patients (31.0 months; P=0.0029).
  • HER2 expression was linked to increased recurrence and metastatic progression, particularly in bladder and renal pelvis tumors.

Conclusions

  • HER2 expression is prevalent in a significant portion of urothelial carcinoma cases.
  • HER2-positive status is associated with aggressive tumor features and worse prognostic outcomes.
  • These findings support the investigation of HER2-targeted therapies for urothelial carcinoma.

Keywords: